



17. JUN. 2005 11:35

WOLFFPATENT JRLM ISRAEL 6242266

NO. 71: P. 2

Docket No. 56040-B/JPW/GJG/DJK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Yaakov Naparstek
Serial No.: 09/826,069 Examiner: G.R. Ewoldt
Filed : April 4, 2001 Group Art Unit: 1644
For : PEPTIDES FOR THE TREATMENT OF SYSTEMIC LUPUS
ERYTHEMATOSUS AND METHODS OF TREATING SYSTEMIC
LUPUS ERYTHEMATOSUS

1185 Avenue of the Americas
New York, New York 10036

Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450

Sir:

DECLARATION OF YAAKOV NAPARSTEK UNDER 37 C.F.R. §1.132

I, Yaakov Naparstek, hereby declare as follows:

1. I am the inventor of the subject matter claimed in the above-identified patent application.
2. I have prepared a sterile 50 ml R-38-Sepharose column for specific extracorporeal immunoadsorption for SLE patients. 5 ml samples of the R-38-Sepharose beads were used to test their ability to remove anti-R-38 lupus antibodies. The lupus antibodies were transferred on the column and the flow-through fractions were tested for binding to R-38 by ELISA.
3. 61-86% of the lupus antibodies were removed as shown in Table 1 below.

Applicant : Yaakov Naparstek
Serial No.: 09/826,069
Filed : April 4, 2001
Page 2

Table 1 - R-38 Binding of SLE Antibodies⁽¹⁾

Antibodies	Pre column	After immunoabsorption	% reduction of O.D.
C72 Antibody ⁽²⁾ (AntiDNA)	1.513	0.21	86.2%
SLE patient ⁽³⁾ D.A.	0.925	0.359	61.2%

- (1) Measured by O.D. 405 in an ELISA test.
(2) 100 ml of the monoclonal mouse anti DNA antibody C72 were transferred on a 5 ml sample from a 50 ml R-38 Sepharose column. The R-38 binding was reduced from 1.513 to 0.21 after adsorption.
(3) Plasma from an SLE patient D.A. was diluted 1:100. Four ml filtered plasma was put on the R-38 column. The binding was reduced from 0.925 to 0.359.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that any such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Yaakov Naparstek
Yaakov Naparstek

19/6/05
Date